Table 1 Patients’ characteristics according to receptor stable and any receptor conversion
Characteristics | All patients | Receptor stable | Any receptor conversion | P |
|---|---|---|---|---|
(N = 231) | (N = 176) | (N = 55) | ||
Age, years | ||||
≤ 50 | 158 (68.4) | 113 (64.2) | 45 (81.8) | 0.014 |
> 50 | 73 (31.6) | 63 (35.8) | 10 (18.2) | |
Initial tumor stage | ||||
T1 | 41 (17.7) | 34 (19.3) | 7 (12.7) | 0.500 |
T2 | 119 (51.5) | 90 (51.1) | 29 (52.7) | |
T3 or T4 | 71 (30.7) | 52 (29.5) | 19 (34.5) | |
Initial node status | ||||
Negative | 32 (13.9) | 22 (12.5) | 10 (18.2) | 0.287 |
Positive | 199 (86.1) | 154 (87.5) | 45 (81.8) | |
Nuclear grade | ||||
1 or 2 | 74 (32.0) | 60 (56.6) | 14 (46.7) | 0.335 |
3 | 62 (26.8) | 46 (43.4) | 16 (53.3) | |
NA | 95 (41.1) | – | – | |
Histology | ||||
IDC | 201 (87.0) | 154 (87.5) | 47 (85.5) | 0.832 |
Mixed | 17 (7.4) | 13 (7.4) | 4 (7.3) | |
Other | 13 (5.6) | 9 (5.1) | 4 (7.3) | |
Initial ER status | ||||
Negative | 10 (4.3) | 3 (1.7) | 7 (12.7) | < 0.001 |
Positive | 221 (95.7) | 173 (98.3) | 48 (87.3) | |
Initial PR status | ||||
Negative | 31 (13.4) | 18 (10.2) | 13 (23.6) | 0.011 |
Positive | 200 (86.6) | 158 (89.8) | 42 (76.4) | |
Initial HER2 status | ||||
Negative | 194 (84.0) | 150 (85.2) | 44 (80.0) | 0.356 |
Positive | 37 (16.0) | 26 (14.8) | 11 (20.0) | |
Initial Ki-67 status | ||||
< 15% | 59 (25.5) | 48 (27.3) | 11 (20.0) | 0.280 |
≥ 15% | 172 (74.5) | 128 (72.7) | 44 (80.0) | |
NAC cycles | ||||
1–4 | 153 (66.2) | 117 (66.5) | 36 (65.5) | 0.889 |
5–8 | 78 (33.8) | 59 (33.5) | 19 (34.5) | |
NAC regimens | ||||
Anthracycline-based | 71 (30.7) | 53 (30.1) | 18 (32.7) | 0.879 |
Anthracycline- and taxane-based | 140 (60.6) | 107 (60.8) | 33 (60.0) | |
Taxane-based | 20 (8.7) | 16 (9.1) | 4 (7.3) | |